The Most Valuable Patents in History

A patent is a monopoly with an expiration date. The most valuable patents in history aren’t the ones that stayed valid the longest — they’re the ones whose monopoly window aligned with the moment a market exploded. Bell’s telephone patent turned a hand-built lab device into a national utility. PageRank turned a Stanford PhD paper into the most profitable advertising business ever built. The original Pfizer atorvastatin patent generated more revenue, in inflation-adjusted dollars, than the entire annual GDP of New Zealand. Below are ten patents whose direct downstream economic value runs into the hundreds of billions, with the live USPTO records linked for each.

10 of the most valuable U.S. patents ever granted

1. Alexander Graham Bell — the telephone. Granted March 7, 1876. The 17-year monopoly created the Bell Telephone Company, which became AT&T, which by the 1980s was one of the largest corporations on earth. The patent itself spawned over 600 lawsuits during its term, all of which Bell won. By any reasonable accounting, the most economically consequential patent in U.S. history.
2. Larry Page & Sergey Brin — PageRank. US 6,285,999 — Method for node ranking in a linked database. Filed 1998, expired 2018. Assigned to Stanford, exclusively licensed to Google. When the patent expired, Stanford had received approximately $337 million in cumulative royalties — and Google had used the 20-year exclusivity window to build a $1.8T company on top of it. Stanford is widely cited as the highest-yielding single university IP transfer in history.
3. Pfizer / Warner-Lambert — atorvastatin (Lipitor). US 4,681,893 — Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis. Granted 1987, expired 2011. Lipitor became the highest-grossing prescription drug in pharmaceutical history — over $125 billion in cumulative revenue during the patent term. When the patent expired, Pfizer’s share price absorbed the loss within a quarter; that’s how reliably blockbuster drug patents are valued by markets.
4. Thomas Edison — incandescent lamp. US 223,898 — Electric lamp. Granted January 27, 1880. The patent that created the Edison Electric Light Company, which merged with Thomson-Houston in 1892 to become General Electric. GE’s peak market capitalization passed $600 billion in 2000. The original lamp patent was litigated relentlessly and upheld; it’s the lineage of every consumer lighting company alive today.
5. Edwin Land — instant photography. US 2,543,181 — Photographic product comprising a rupturable container carrying a photographic processing liquid. Land’s self-developing film chemistry built Polaroid into a company worth roughly $14 billion at its 1990s peak. When Kodak began selling instant cameras in 1976, Land sued and won the largest patent infringement judgment in history at the time — $909 million in 1990 (over $2 billion today).
6. RSA Data Security — public-key cryptography. US 4,405,829 — Cryptographic communications system and method. Filed 1977, expired 2000. Issued to Rivest, Shamir, and Adleman. Every secure web transaction in the world ran on RSA-licensed cryptography for 23 years. Verisign acquired RSA Security for $1.4 billion in 2006; the underlying patent had already expired but the brand and follow-on patents carried the value forward.
7. Stanley Cohen & Herbert Boyer — recombinant DNA. US 4,237,224 — Process for producing biologically functional molecular chimeras. Filed 1974, expired 1997. Stanford and UC licensed it to virtually every biotechnology company that existed in the 1980s and 1990s. Cumulative licensing revenue exceeded $250 million for the universities; the underlying technique generated essentially the entire modern biotech industry.
8. Carl Djerassi (Syntex) — synthetic oral contraceptive. US 2,744,122 — Δ4 19-nor-17α-ethinyl-androsten-17β-ol-3-one. The synthesis of norethindrone in 1951 led to Enovid, the first oral contraceptive, and turned a small Mexican pharmaceutical firm into a multinational. Syntex was acquired by Roche for $5.3 billion in 1994. The downstream economic and social impact is incalculable.
9. Apple — slide-to-unlock and pinch-to-zoom. US 7,479,949 — Touch screen device, method, and graphical user interface for determining commands by applying heuristics. The “Steve Jobs patent” covering iPhone touch interpretation. Apple used it as the centerpiece of the $1B+ Apple v. Samsung judgment in 2012. The patent itself expired in 2027 (counting from 2007 filing) but Apple harvested roughly a decade of injunction leverage.
10. Eli Whitney — cotton gin. US X72 — Cotton gin. Granted 1794. Whitney’s patent was so widely infringed that he died nearly broke, but the underlying technology changed the entire economic geography of the antebellum South and turned cotton into the leading U.S. export for half a century. A cautionary tale: the value of an invention to an economy is often disconnected from the value of the patent to its inventor.

How a patent’s value is actually measured

Patent valuation is a discipline of its own. The three approaches investment bankers and IP consultancies use:

• Income method. Project the future cash flows attributable to the patent (licensing royalties, premium product margins, defensive value against competitors) and discount to present value. This is how blockbuster drug patents are valued — the discounted cash flow of the protected revenue stream over the remaining term.
• Market method.Look at recent comparable patent transactions in the same field. Useful for portfolio sales (e.g. when Nortel’s 6,000-patent portfolio sold for $4.5B in 2011 to a consortium of Apple, Microsoft, and others — roughly $750k per patent average).
• Cost method. What would it cost a competitor to design around or independently develop the same protection? Used for foundational patents in mature fields where neither comparable transactions nor reliable royalty data exist.

Most truly valuable patents are valued by the income method, because the value comes from the protected revenue stream, not the patent itself.

What expired blockbuster patents teach modern inventors

Read through the expiration dates above. Almost every patent on this list expired within the last 20 years — and almost every assignee company is still dominant in its market. That tells you something important: the patent itself doesn’t generate the value; the patent buys you the time to build distribution, brand, manufacturing, and engineering depth that make you defensible after the patent is gone.

Pfizer doesn’t need the Lipitor patent anymore — it has decades of cardiology relationships, manufacturing scale, and a brand pharmacists trust. Google doesn’t need PageRank — it has 25 years of crawl data, ad-targeting infrastructure, and the default-search slot in most browsers. The patent was the moat builder, not the moat itself. That’s the real lesson for any inventor reading this: the patent is a 12-to-20-year head start. What you build during the head start is what actually compounds.

The single most-valuable patent class today

The valuation models above all converge on one current answer: composition-of-matter patents on small-molecule pharmaceuticals.The reason is structural — under U.S. law, generic drug manufacturers cannot legally produce a covered molecule until the composition patent expires, no matter how the molecule is synthesized. Software, electronics, and even mechanical patents can almost always be designed around with enough engineering investment. A novel chemical compound can’t.

Of the top 50 highest-grossing drugs of all time, almost every one is anchored to a composition-of-matter patent like the Lipitor entry above. This is why the biotech-patent strategy and the software-patent strategy look so different in practice — and why pharma is the field where patents are most fiercely litigated.

From our spoke library

Our 1,962-patent library focuses on consumer products rather than pharma or telecom — but several of the highest-citation entries hint at the same compounding dynamic. Here are some highly-cited spokes that built durable consumer brands:

• US 5,325,765 — Keurig K-Cup beverage cartridge
• US 4,802,444 — Kong Company indestructible pet toy
• US 2,487,400 — Earl Tupper’s airtight container seal

(If a link 404s, the patent hasn’t been pulled into our daily spoke set yet — USPTO records on Google Patents are always authoritative.)

What this means for your invention

You’re probably not Alexander Graham Bell. But the framework above still applies: file early, lock in your priority date, and use the protected window to build whatever non-patent moat you can — distribution, manufacturing, customer relationships, brand. The patent is the runway. The business is the airplane.

The cheapest first step is a provisional application. $65 at the micro-entity tier gets you 12 months of “patent pending” status while you decide whether to pursue a full utility filing.

File a provisional patent application with LegalZoom →

(Affiliate link — we may earn a commission at no extra cost to you.)

Read next

• Famous patented products — the consumer brands built on a single foundational patent.
• The history of U.S. patent law — how the system that protected these inventions evolved.
• How to patent an idea — the procedural roadmap, start to finish.